Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for PAH, a rare, female predominant disease

SEOUL, South Korea, July 2, 2023 /PRNewswire/ — Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop ZMA001 for the treatment of pulmonary arterial hypertension (PAH).

View Source: https://finance.yahoo.com/news/zymedi-announced-collaboration-national-heart-000000695.html?guccounter=1


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2010-2024 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?